(GLOBE NEWSWIRE via COMTEX) --
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced upcoming presentations at two investor conferences in May 2024.
Conference: Aegis Capital Virtual Healthcare Conference
Date: Wednesday May 8, 2024, 11 AM EST
Location: Virtual
Presenter: Gary Jacob, PhD, Chief Executive Officer
Conference: Citizens JMP Securities Life Sciences Conference
Date: Monday May 13, 2024, 10:30 AM EST
Location: New York, NY
Presenter: Gary Jacob, PhD, Chief Executive Officer
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
Enquiries:
OKYO Pharma Limited Gary S. Jacob, Chief Executive Officer 917-497-7560
Business Development & Investor Relations Paul Spencer +44 (0)20 7495 2379
COMTEX_452057837/2241/2024-05-08T07:00:03
Copyright (C) 2024 GLOBE NEWSWIRE. All rights reserved.
